Volume 58, Issue 6, Pages (December 2000)

Slides:



Advertisements
Similar presentations
Volume 62, Pages S12-S22 (December 2002)
Advertisements

Volume 66, Issue 4, Pages (October 2004)
Volume 60, Issue 3, Pages (September 2001)
Volume 58, Issue 5, Pages (November 2000)
Volume 54, Issue 5, Pages (November 1998)
Volume 68, Issue 2, Pages (August 2005)
Volume 68, Issue 6, Pages (December 2005)
Volume 58, Issue 5, Pages (November 2000)
Volume 80, Issue 6, Pages (September 2011)
Volume 64, Pages S27-S32 (October 2003)
Volume 54, Issue 3, Pages (September 1998)
The Case ∣ Acute renal failure and anemia
Volume 58, Issue 1, Pages (July 2000)
Volume 56, Pages S31-S36 (July 1999)
Volume 60, Issue 2, Pages (August 2001)
Volume 64, Issue 2, Pages (August 2003)
Volume 75, Issue 3, Pages (February 2009)
Volume 61, Issue 5, Pages (May 2002)
Volume 58, Issue 6, Pages (December 2000)
Volume 68, Issue 3, Pages (September 2005)
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes  Lesley Wassef, Darren J. Kelly, Richard E. Gilbert 
Volume 63, Issue 1, Pages (January 2003)
Volume 63, Issue 4, Pages (April 2003)
Volume 59, Issue 1, Pages (January 2001)
Volume 65, Issue 1, Pages (January 2004)
Volume 54, Issue 1, Pages (July 1998)
Volume 59, Issue 4, Pages (April 2001)
Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada 
Karl A. Nath, Anthony J. Croatt, Jill J. Haggard, Joseph P. Grande 
Volume 60, Issue 3, Pages (September 2001)
Volume 62, Issue 4, Pages (October 2002)
Volume 57, Issue 5, Pages (May 2000)
Volume 65, Issue 6, Pages (June 2004)
Volume 62, Issue 3, Pages (September 2002)
Volume 60, Issue 6, Pages (December 2001)
Volume 61, Issue 1, Pages (January 2002)
Volume 59, Issue 2, Pages (February 2001)
Volume 64, Issue 3, Pages (September 2003)
Volume 61, Issue 6, Pages (June 2002)
Volume 66, Issue 4, Pages (October 2004)
Volume 59, Issue 3, Pages (March 2001)
In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry  Miguel Angel Hernández-Presa, Carmen Gómez-Guerrero,
Volume 60, Issue 6, Pages (December 2001)
Volume 62, Pages S12-S22 (December 2002)
Volume 54, Pages S22-S28 (September 1998)
Calcitonin receptor isoforms expressed in the developing rat kidney
Volume 54, Issue 4, Pages (October 1998)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 56, Issue 2, Pages (August 1999)
STAT proteins mediate angiotensin II–induced production of TIMP-1 in human proximal tubular epithelial cells  Xiangmei Chen, Jianzhong Wang, Feng Zhou,
Volume 59, Issue 5, Pages (May 2001)
Volume 64, Pages S21-S26 (October 2003)
Volume 59, Issue 5, Pages (May 2001)
Lipopolysaccharide Potentiates the Effect of Hepatocyte Growth Factor upon Replication in Lung, Thyroid, Spleen, and Colon in Rats in Vivo  Cuihua Gao,
Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: Impact on proliferation and apoptosis  Shao-Ling Zhang, Jun Guo, Babak Moini, Julie.
Ho Jae Han, Soo Hyun Park, Hyun Ju Koh, Mary Taub  Kidney International 
Volume 54, Pages S36-S40 (December 1998)
Volume 64, Issue 1, Pages (July 2003)
Volume 62, Issue 4, Pages (October 2002)
Volume 58, Issue 4, Pages (October 2000)
Volume 56, Issue 6, Pages (December 1999)
Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes  Guorong Ma, Terri J. Allen, Mark E. Cooper,
Volume 63, Issue 1, Pages (January 2003)
Volume 72, Issue 11, Pages (December 2007)
Volume 58, Issue 6, Pages (December 2000)
Volume 60, Issue 5, Pages (November 2001)
Volume 55, Issue 3, Pages (March 1999)
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?  Richard E. Gilbert, Mark E. Cooper  Kidney.
Volume 70, Issue 9, Pages (November 2006)
Eric N Haugen, Anthony J Croatt, Karl A. Nath  Kidney International 
Presentation transcript:

Volume 58, Issue 6, Pages 2437-2451 (December 2000) Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis  Zemin Cao, Darren J. Kelly, Alison Cox, David Casley, Josephine M. Forbes, Paul Martinello, Rachael Dean, Richard E. Gilbert, Mark E. Cooper  Kidney International  Volume 58, Issue 6, Pages 2437-2451 (December 2000) DOI: 10.1046/j.1523-1755.2000.00427.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Representative macroscopic autoradiographs of in vitro total binding for 125I-CGP42112B in rat embryo (A, total binding; D, nonspecific binding) and the kidney sections from rats at the age of 8 (B, total binding; E, nonspecific binding) and 24 weeks (C, total binding; F, nonspecific binding). Reproduction of this figure in color was sponsored by Novartis Pharmaceuticals. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Total binding (•) and nonspecific binding (○) for 125I-CGP42112B (A) and percentage of specific/total binding (B) in the adult kidney at increasing concentrations of the radioligand. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Representative macroscopic autoradiographs of in vitro 125I-CGP42112B binding. Sections were incubated with 125I-CGP42112B (15 pmol/L) alone (A) or in the presence of 10-5 mol/L of Ang II (B), valsartan (C), PD123319 (D), nonradioactive CGP42112B (E), and GTP-γ-S (F). Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Data of in vitro binding densities for 125I-CGP42112B in the kidney cortex area were assessed using MCID system. *P < 0.01 vs. total binding. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Representative macroscopic autoradiographs of in vivo 125I-CGP42112B binding.125I-CGP42112B was infused into rat aorta following injection of PBS (A, total binding) or PBS with 10-5 mol/L of Ang II (B), valsartan (C), PD123319 (D), nonradioactive CGP42112B (E). Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 6 Slides coated with photographic emulsion showing localization of 125I-CGP 42112B in vivo binding sites.125I-CGP42112B was infused into rat aorta following injection of PBS (A, total binding) or PBS with 10-5 mol/L of nonradioactive CGP42112B (B, nonspecific binding). Silver grains (black dots) overlying cells in glomeruli and proximal convoluted tubules represent 125I-CGP 42112B binding sites (A and C). The slide (C) shows double labeling of photographic emulsion (black dots, total binding) with lectin stain (brown) in the kidney section from a rat injected with radioligand. Sections are stained with hematoxylineosin (A and B) or hematoxylin with absence of eosin (C). Original magnification ×400. Reproduction of this figure in color was sponsored by Novartis Pharmaceuticals. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 7 PCNA- and TUNEL-positive cells in proximal tubules were identified as brown in nuclei. Sections showed PCNA-positive cells in control (A) and high-dose Ang II (C), Ang II + valsartan (E) or Ang II + PD123310 (G), and TUNEL-positive cells in control (B), high-dose Ang II (D), Ang II + valsartan (F) or Ang II + PD123319 (H). Sections were counterstained with hematoxylin. Original magnification ×400. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 8 PCNA- (□) and TUNEL- (▪) positive cell numbers in the proximal tubules following Ang II infusion, and treatment with valsartan or PD123319. *P < 0.01 vs. control; †P < 0.01 vs. high-dose Ang II; #P < 0.05 vs. Ang II + valsartan. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 9 Double labeling of TUNEL with PCNA in the renal tubules after Ang II infusion. TUNEL positive cells were identified as brown in nuclei (↑) and PCNA as dark blue (↑↑); some cells stained positively for both (*↑), counterstain with eosin. Original magnification ×1000. Reproduction of this figure in color was sponsored by Novartis Pharmaceuticals. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 10 Representative macroscopic autoradiographs of gene expression of osteopontin by in situ hybridization in control (A), high-dose Ang II (B), Ang II + valsartan (C), and Ang II + PD123319 (D). Reproduction of this figure in color was sponsored by Novartis Pharmaceuticals. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 11 Slides coated with photographic emulsion showing osteopontin mRNA expression by in situ hybridization in control (A), high-dose Ang II (C), Ang II + valsartan (E), and Ang II + PD123319 (G); and immunohistochemical staining of monoclonal antibody to osteopontin in control (B), high-dose Ang II (D), Ang II + valsartan (F) Ang II + PD123319 (G). Original magnification ×400. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 12 Data for gene expression of osteopontin was assessed with MCID system following Ang II infusion or coadministration of valsartan or PD123319. *P < 0.01 vs. control; †P < 0.01 vs. high-dose Ang II. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 13 Binding densities of Ang II (□) and AT1R (▪) by autoradiography with 125I-Sar1, Ile8 Ang II (A) and binding density of the AT2R (□) by autoradiography with 125I-CGP42112B (B). *P < 0.01, vs. control; ‡P < 0.05 vs. high-dose Ang II. Kidney International 2000 58, 2437-2451DOI: (10.1046/j.1523-1755.2000.00427.x) Copyright © 2000 International Society of Nephrology Terms and Conditions